<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02413281</url>
  </required_header>
  <id_info>
    <org_study_id>ALK5461-212</org_study_id>
    <nct_id>NCT02413281</nct_id>
  </id_info>
  <brief_title>A Study of the Abuse Liability Potential of ALKS 5461 in Healthy, Non-Dependent, Recreational Opioid Users</brief_title>
  <official_title>A Phase 1, Single-Dose, Double-Blind, Placebo-and Active-Controlled, Randomized, 6-way Crossover Human Abuse Liability Evaluation of ALKS 5461</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkermes, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkermes, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the abuse potential of ALKS 5461.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacodynamics: Abuse potential measured by visual analog scales (VAS)</measure>
    <time_frame>Approximately 14 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence of adverse events (AEs)</measure>
    <time_frame>Up to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Plasma concentrations of ALKS 5461</measure>
    <time_frame>Up to 14 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ALKS 5461 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sublingual tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALKS 5461 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sublingual tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALKS 5461 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sublingual tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Buprenorphine Dose 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sublingual tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Buprenorphine Dose 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sublingual tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sublingual tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALKS 5461</intervention_name>
    <description>Sublingual tablets, single administration</description>
    <arm_group_label>ALKS 5461 Dose 1</arm_group_label>
    <arm_group_label>ALKS 5461 Dose 2</arm_group_label>
    <arm_group_label>ALKS 5461 Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>Sublingual tablets, single administration</description>
    <arm_group_label>Buprenorphine Dose 1</arm_group_label>
    <arm_group_label>Buprenorphine Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sublingual tablets, single administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a body mass index (BMI) within the range of 18.0 to 30.0 kg/m2, inclusive, and a
             minimum weight of at least 50.0 kg

          -  Be a current recreational opioid user who has used opioids for non-therapeutic
             purposes (ie for psychoactive effects) at least 10 times in their lifetime

          -  Agree to use an approved method of contraception for the duration of the study unless
             surgically sterile or postmenopausal

          -  Be willing and able to abide by all study requirements and restrictions

          -  Additional criteria may apply

        Exclusion Criteria:

          -  Have evidence of drug or alcohol dependence within the past 2 years

          -  Have a positive drug screen for opioids, amphetamines, cocaine, or benzodiazepines
             upon admission to the clinic

          -  Have a history of severe allergic reaction (including anaphylaxis) to any food,
             medication, or bee sting

          -  Be currently pregnant, breastfeeding, or planning to become pregnant during the study

          -  Currently have or have a history of allergy or hypersensitivity to opioid agonists,
             opioid antagonists or related drugs (eg, oxycodone, morphine, naltrexone, and
             naloxone)

          -  Have a positive test result for hepatitis B, hepatitis C, or human immunodeficiency
             virus (HIV)

          -  Have donated or lost more than 500 mL whole blood

          -  Additional criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjeev Pathak, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alkermes, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2015</study_first_submitted>
  <study_first_submitted_qc>April 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2015</study_first_posted>
  <last_update_submitted>November 9, 2015</last_update_submitted>
  <last_update_submitted_qc>November 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Volunteer</keyword>
  <keyword>Abuse Liability</keyword>
  <keyword>ALKS 5461</keyword>
  <keyword>Alkermes</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

